Richard A. F. Dixon

7 Hills Pharma LLC is a clinical-stage pharmaceutical company based in Houston, TX. The private company is developing first-in-concept integrin activators to augment immunotherapies for the treatment of drug-resistant solid tumors and infectious diseases. The lead compound, 7HP349, is an oral VLA-4/LFA-1 allosteric activator that will be in phase I testing for PD-1 refractory solid tumors and geriatric influenza. The company's compounds are expected to augment antigen presentation and immune priming to facilitate a productive immune response against a variety of antigens. 7 Hills Pharma is managed by an experienced group of pharmaceutical executives, including Richard A. F. Dixon, Upendra K. Marathi, Kala Marathi, Peter Vanderslice, and Darren Woodside. Upendra K. Marathi has been the CEO since incorporation.

Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX.